Trial Profile
A Signal Finding Phase 2 Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) and Relatlimab (Anti-LAG-3 Monoclonal Antibody; BMS-986016) in Patients With Advanced Chordoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- 12 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Apr 2023 Planned End Date changed from 3 Apr 2024 to 3 Apr 2025.
- 12 Apr 2023 Planned primary completion date changed from 3 Apr 2023 to 3 Apr 2024.